Yumanity Therapeutics, Inc.
40 Guest Street, Suite 4410
Boston, MA 02135
December 20, 2021
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Yumanity Therapeutics, Inc.: Registration Statement on Form S-3 filed December 3, 2021 (File No. 333-261489), as amended on December 20, 2021.
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Yumanity Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to December 22, 2021, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Jesse Nevarez of Goodwin Procter LLP at (212) 459-7327.
| Sincerely, |
| Yumanity Therapeutics, Inc. |
/s/ Richard Peters |
| Richard Peters |
| President and Chief Executive Officer |
| cc: | Devin Smith, Yumanity Therapeutics, Inc. | |
| Jesse Nevarez, Esq., Goodwin Procter LLP |
